FOS and steatosis: Consequently, NAS-induced phenotypes, such as hepatic inflammation and steatosis, were markedly ameliorated, manifested by recovery of the serum LPS level and reductions in the accompanying systemic inflammation and lipid dysmetabolism of mice after supplementation with metformin or FOS.